Aratana Therapeutics Stock Price, News & Analysis (NASDAQ:PETX)

$4.09 +0.05 (+1.24 %)
(As of 02/25/2018 12:35 PM ET)
Previous Close$4.09
Today's Range$3.93 - $4.13
52-Week Range$3.91 - $7.67
Volume256,778 shs
Average Volume252,376 shs
Market Capitalization$175.87 million
P/E Ratio-2.82
Dividend YieldN/A
Beta3.07

About Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Veterinary Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PETX
CUSIPN/A
Phone913-353-1000

Debt

Debt-to-Equity Ratio0.26%
Current Ratio3.42%
Quick Ratio3.08%

Price-To-Earnings

Trailing P/E Ratio-2.82068965517241
Forward P/E Ratio-3.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$38.55 million
Price / Sales4.56
Cash FlowN/A
Price / CashN/A
Book Value$2.44 per share
Price / Book1.68

Profitability

Trailing EPS($1.45)
Net Income$-33,570,000.00
Net Margins-358.55%
Return on Equity-48.79%
Return on Assets-30.52%

Miscellaneous

Employees85
Outstanding Shares43,000,000

Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) posted its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03. The biopharmaceutical company earned $6.16 million during the quarter, compared to analysts' expectations of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. Aratana Therapeutics's revenue for the quarter was up 1440.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.38) earnings per share. View Aratana Therapeutics' Earnings History.

When will Aratana Therapeutics make its next earnings announcement?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 13th 2018. View Earnings Estimates for Aratana Therapeutics.

Where is Aratana Therapeutics' stock going? Where will Aratana Therapeutics' stock price be in 2018?

5 equities research analysts have issued twelve-month price objectives for Aratana Therapeutics' shares. Their predictions range from $6.00 to $10.00. On average, they expect Aratana Therapeutics' stock price to reach $8.75 in the next year. View Analyst Ratings for Aratana Therapeutics.

What are Wall Street analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (1/17/2018)
  • 2. HC Wainwright analysts commented, "Galliprant Approved in EU; Additional Product Approvals Expected in 2018; Reiterate Buy Galliprant approved for canine osteoarthritis in Europe. On January 11, Aratana announced that the EMA has granted Galliprant marketing approval for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Galliprant is licensed to Elanco, the animal health division of Eli Lilly (LLY; not rated), who has exclusive rights to commercialize the drug globally. Galliprant was first approved in the US in March 2016, and in the nine months ended September 30, 2017, generated approximately $9M in product sales and $4M in license and collaboration revenue for Aratana. Going forward, Elanco has assumed all development, regulatory and manufacturing responsibilities for Galliprant, and we expect the company to launch the drug in Europe in 2Q18." (1/16/2018)
  • 3. Jefferies Group LLC analysts commented, "Q4'16 results uneventful. The Nocita and Galliprant launches are progressing and Entyce is on track for late '17 launch. However, we think the sell-off on the Q4 results was primarily driven by concerns around the cash runway and how this will be addressed. We like the risk/ reward at this level and reiterate our Buy rating. PT lowered to $8 (from $11)." (3/16/2017)

Who are some of Aratana Therapeutics' key competitors?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:

  • Wendy L. Yarno, Chairman of the Board (Age 63)
  • Steven St. Peter M.D., President, Chief Executive Officer, Director (Age 49)
  • Craig A. Tooman, Chief Financial Officer, Treasurer (Age 49)
  • Brent Standridge, Chief Operating Officer (Age 58)
  • Ernst Heinen Ph.D., Chief Development Officer (Age 52)
  • Laura A. Brege, Independent Director (Age 59)
  • David L. Brinkley, Independent Director (Age 57)
  • Robert Benthall Gerber Jr., Independent Director (Age 52)
  • Irvine O. Hockaday Jr. Esq., Independent Director (Age 81)
  • Merilee Raines, Independent Director (Age 61)

Who owns Aratana Therapeutics stock?

Aratana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (13.81%), Broadfin Capital LLC (9.99%), BlackRock Inc. (7.13%), AWM Investment Company Inc. (3.44%), General American Investors Co. Inc. (2.60%) and Millennium Management LLC (1.44%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, Julia A Stephanus and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Who sold Aratana Therapeutics stock? Who is selling Aratana Therapeutics stock?

Aratana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Franklin Resources Inc., AWM Investment Company Inc., BlackRock Inc., TIAA CREF Investment Management LLC and Mariner Wealth Advisors LLC. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Who bought Aratana Therapeutics stock? Who is buying Aratana Therapeutics stock?

Aratana Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, General American Investors Co. Inc., Wells Fargo & Company MN, Granite Investment Partners LLC, Ellington Management Group LLC, Deutsche Bank AG, Renaissance Technologies LLC and Sheaff Brock Investment Advisors LLC. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy Aratana Therapeutics stock?

Shares of Aratana Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of Aratana Therapeutics stock can currently be purchased for approximately $4.09.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $175.87 million and generates $38.55 million in revenue each year. The biopharmaceutical company earns $-33,570,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (PETX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aratana Therapeutics (NASDAQ:PETX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.75$8.75$9.00$8.33
Price Target Upside: 67.62% upside67.62% upside29.68% upside55.18% upside

Aratana Therapeutics (NASDAQ:PETX) Consensus Price Target History

Price Target History for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
12/27/2017CL KingInitiated CoverageNeutral -> NeutralLowView Rating Details
12/18/2017Stifel NicolausReiterated RatingHold$6.00HighView Rating Details
11/16/2017Jefferies GroupSet Price TargetBuy$9.00N/AView Rating Details
8/25/2017Lake Street CapitalLower Price TargetBuy -> Buy$15.00 -> $10.00LowView Rating Details
2/9/2017William BlairReiterated RatingOutperformN/AView Rating Details
8/11/2016BarclaysLower Price TargetOverweight$15.00 -> $11.00N/AView Rating Details
8/10/2016Credit Suisse GroupReiterated RatingBuy$11.00N/AView Rating Details
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

Aratana Therapeutics (NASDAQ:PETX) Earnings History and Estimates Chart

Earnings by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ PETX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.23)N/AView Earnings Details
11/2/2017Q3 2017($0.24)($0.21)$6.47 million$6.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.29)($0.26)$4.50 million$5.16 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.34)($0.34)$3.05 million$3.80 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.42)($0.64)$0.80 million$0.29 millionViewN/AView Earnings Details
11/3/2016Q316($0.48)($0.38)$0.13 million$0.04 millionViewN/AView Earnings Details
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)$0.14 million$0.30 millionViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40$0.12 millionViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Aratana Therapeutics (NASDAQ:PETX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.18)($0.16)($0.17)
Q2 20182($0.15)($0.13)($0.14)
Q3 20182($0.14)($0.08)($0.11)
Q4 20182($0.04)$0.24$0.10
Q1 20192($0.10)$0.03($0.04)
Q2 20192$0.02$0.06$0.04
Q3 20191$0.10$0.10$0.10
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Aratana Therapeutics (NASDAQ:PETX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aratana Therapeutics (NASDAQ PETX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 71.06%
Insider Trades by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ PETX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/30/2018Peter Steven StCEOSell19,367$4.77$92,380.59672,259View SEC Filing  
1/11/2018Craig A ToomanInsiderSell30,000$5.27$158,100.0075,024View SEC Filing  
12/1/2017Healthcare Master Fun BroadfinMajor ShareholderSell890,516$5.70$5,075,941.20View SEC Filing  
11/29/2017Healthcare Master Fun BroadfinMajor ShareholderSell116,516$6.53$760,849.48View SEC Filing  
11/10/2017Peter Steven StInsiderSell50,000$7.00$350,000.00529,359View SEC Filing  
10/2/2017Peter Steven StInsiderSell50,000$6.24$312,000.00View SEC Filing  
9/25/2017Brent StandridgeCOOSell10,000$6.11$61,100.0070,267View SEC Filing  
9/15/2017Ernst HeinenInsiderSell10,000$6.25$62,500.00130,994View SEC Filing  
4/17/2017Peter Steven StInsiderSell50,000$5.54$277,000.00582,693View SEC Filing  
1/27/2017Peter Steven StInsiderSell50,000$7.72$386,000.00632,693View SEC Filing  
12/15/2016Peter Steven StInsiderSell50,000$7.63$381,500.00592,793View SEC Filing  
10/3/2016Ernst HeinenInsiderSell10,000$10.00$100,000.00115,494View SEC Filing  
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.0072,424View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00642,793View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00127,503View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00717,793View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00125,494View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16102,424View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.4069,980View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.0073,600View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.0095,294View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aratana Therapeutics (NASDAQ PETX) News Headlines

Source:
DateHeadline
Aratana Therapeutics Inc (PETX) Receives Average Rating of "Hold" from AnalystsAratana Therapeutics Inc (PETX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 24 at 1:32 PM
Technical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana TherapeuticsTechnical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics
www.bizjournals.com - February 23 at 9:04 AM
Aratana Therapeutics to Report Fourth Quarter and Full Year 2017 Financial ResultsAratana Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 13 at 9:30 AM
Aratana Therapeutics Inc (PETX) Expected to Post Earnings of -$0.23 Per ShareAratana Therapeutics Inc (PETX) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - February 12 at 1:20 PM
Aratana Therapeutics Inc (PETX) CEO Peter Steven St Sells 19,367 SharesAratana Therapeutics Inc (PETX) CEO Peter Steven St Sells 19,367 Shares
www.americanbankingnews.com - February 1 at 6:28 PM
Aratana Therapeutics Inc (PETX) Receives Consensus Rating of "Hold" from BrokeragesAratana Therapeutics Inc (PETX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 30 at 1:32 PM
Zacks: Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Quarterly Sales of $5.72 MillionZacks: Brokerages Expect Aratana Therapeutics Inc (PETX) Will Post Quarterly Sales of $5.72 Million
www.americanbankingnews.com - January 28 at 4:12 AM
Aratana Therapeutics (PETX) Lowered to Sell at Zacks Investment ResearchAratana Therapeutics (PETX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 17 at 11:26 AM
Aratana Therapeutics (PETX) Earns Buy Rating from HC WainwrightAratana Therapeutics (PETX) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - January 16 at 8:08 AM
Craig A. Tooman Sells 30,000 Shares of Aratana Therapeutics Inc (PETX) StockCraig A. Tooman Sells 30,000 Shares of Aratana Therapeutics Inc (PETX) Stock
www.americanbankingnews.com - January 12 at 6:58 PM
Lillys Elanco/Aratanas Veterinary Medicine Gets EU NodLilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod
finance.yahoo.com - January 12 at 10:18 AM
Aratana Therapeutics Inc (PETX) Expected to Announce Quarterly Sales of $5.72 MillionAratana Therapeutics Inc (PETX) Expected to Announce Quarterly Sales of $5.72 Million
www.americanbankingnews.com - January 11 at 7:02 AM
Aratana Therapeutics Inc (PETX) Expected to Announce Earnings of -$0.23 Per ShareAratana Therapeutics Inc (PETX) Expected to Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 9 at 1:40 PM
Aratana Therapeutics Inc (PETX) Given Average Recommendation of "Hold" by BrokeragesAratana Therapeutics Inc (PETX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 5 at 1:54 PM
ValuEngine Lowers Aratana Therapeutics (PETX) to Strong SellValuEngine Lowers Aratana Therapeutics (PETX) to Strong Sell
www.americanbankingnews.com - January 1 at 1:36 PM
Aratana Therapeutics: Slow Out Of The Gates - Seeking AlphaAratana Therapeutics: Slow Out Of The Gates - Seeking Alpha
seekingalpha.com - December 28 at 8:31 AM
Aratana Therapeutics (PETX) Now Covered by CL KingAratana Therapeutics (PETX) Now Covered by CL King
www.americanbankingnews.com - December 27 at 8:09 AM
Aratana Therapeutics (PETX) Granted Conditional License for Canine Osteosarcoma TherapeuticAratana Therapeutics (PETX) Granted Conditional License for Canine Osteosarcoma Therapeutic
www.streetinsider.com - December 22 at 7:37 PM
Aratana Therapeutics (PETX) Granted Conditional License for Canine Osteosarcoma Therapeutic - StreetInsider.comAratana Therapeutics (PETX) Granted Conditional License for Canine Osteosarcoma Therapeutic - StreetInsider.com
www.streetinsider.com - December 21 at 4:41 PM
Aratana Therapeutics (PETX) Given a $10.00 Price Target by HC Wainwright AnalystsAratana Therapeutics (PETX) Given a $10.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - December 21 at 3:06 PM
Aratana nears approval for canine cancer vaccineAratana nears approval for canine cancer vaccine
www.bizjournals.com - December 21 at 10:16 AM
When will Kansas, Missouri exhaust funding for children’s health insurance?When will Kansas, Missouri exhaust funding for children’s health insurance?
finance.yahoo.com - December 20 at 4:37 PM
William Blair Analysts Increase Earnings Estimates for Aratana Therapeutics Inc (PETX)William Blair Analysts Increase Earnings Estimates for Aratana Therapeutics Inc (PETX)
www.americanbankingnews.com - December 20 at 3:38 PM
Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma TherapeuticAratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic
finance.yahoo.com - December 20 at 10:20 AM
FY2020 EPS Estimates for Aratana Therapeutics Inc Decreased by Analyst (PETX)FY2020 EPS Estimates for Aratana Therapeutics Inc Decreased by Analyst (PETX)
www.americanbankingnews.com - December 19 at 11:58 PM
Aratana Therapeutics (PETX) Receives "Hold" Rating from Stifel NicolausAratana Therapeutics (PETX) Receives "Hold" Rating from Stifel Nicolaus
www.americanbankingnews.com - December 19 at 1:18 PM
Aratanas stock falls after newest pet drug treatment fails studyAratana's stock falls after newest pet drug treatment fails study
finance.yahoo.com - December 18 at 4:37 PM
Mid-Morning Market Update: Markets Open Higher; Hershey To Acquire Amplify Snack Brands For $12/Share - BenzingaMid-Morning Market Update: Markets Open Higher; Hershey To Acquire Amplify Snack Brands For $12/Share - Benzinga
www.benzinga.com - December 18 at 10:41 AM
Aratana Therapeutics (PETX) Reports Study Results for AT-016 - StreetInsider.comAratana Therapeutics (PETX) Reports Study Results for AT-016 - StreetInsider.com
www.streetinsider.com - December 17 at 10:13 AM
Aratana Therapeutics Announces Study Results for AT-016Aratana Therapeutics Announces Study Results for AT-016
finance.yahoo.com - December 15 at 4:54 PM
Aratana Therapeutics, Inc. (PETX) Receives Average Recommendation of "Hold" from BrokeragesAratana Therapeutics, Inc. (PETX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 11 at 4:30 PM
ETFs with exposure to Aratana Therapeutics, Inc. : December 8, 2017ETFs with exposure to Aratana Therapeutics, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 4:35 PM
With its stock still sinking, what it means that Aratana pulled a $35M offeringWith its stock still sinking, what it means that Aratana pulled a $35M offering
www.bizjournals.com - December 7 at 4:55 PM
-$0.23 Earnings Per Share Expected for Aratana Therapeutics, Inc. (PETX) This Quarter-$0.23 Earnings Per Share Expected for Aratana Therapeutics, Inc. (PETX) This Quarter
www.americanbankingnews.com - December 6 at 11:18 AM
Aratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 116,516 SharesAratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 116,516 Shares
www.americanbankingnews.com - December 1 at 9:02 PM
Aratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 890,516 SharesAratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 890,516 Shares
www.americanbankingnews.com - December 1 at 8:38 PM
Aratana cancels stock offering after shares plunge - MarketWatchAratana cancels stock offering after shares plunge - MarketWatch
www.marketwatch.com - November 30 at 10:55 AM
Why Aratana Therapeutics Inc. Is Tanking Today - Motley FoolWhy Aratana Therapeutics Inc. Is Tanking Today - Motley Fool
www.fool.com - November 30 at 10:55 AM
Aratana Therapeutics, Inc. Announces Termination of Offering of Common StockAratana Therapeutics, Inc. Announces Termination of Offering of Common Stock
finance.yahoo.com - November 29 at 10:22 AM
Aratana cancels stock offering after shares plungeAratana cancels stock offering after shares plunge
finance.yahoo.com - November 29 at 10:22 AM
Why Momo, Aratana Therapeutics, and Sea Limited Slumped TodayWhy Momo, Aratana Therapeutics, and Sea Limited Slumped Today
finance.yahoo.com - November 28 at 4:35 PM
Aratana Therapeutics (PETX) Commences $35M Common Stock OfferingAratana Therapeutics (PETX) Commences $35M Common Stock Offering
www.streetinsider.com - November 28 at 10:34 AM
Aratana Therapeutics, Inc. Announces Proposed Public OfferingAratana Therapeutics, Inc. Announces Proposed Public Offering
finance.yahoo.com - November 27 at 4:36 PM
ETFs with exposure to Aratana Therapeutics, Inc. : November 24, 2017ETFs with exposure to Aratana Therapeutics, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 5:42 PM
Aratana Therapeutics, Inc. (PETX) Expected to Post Quarterly Sales of $7.25 MillionAratana Therapeutics, Inc. (PETX) Expected to Post Quarterly Sales of $7.25 Million
www.americanbankingnews.com - November 20 at 6:50 AM
Zacks: Brokerages Expect Aratana Therapeutics, Inc. (PETX) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Expect Aratana Therapeutics, Inc. (PETX) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - November 18 at 1:26 PM
Aratana Therapeutics, Inc. (PETX) Given a $9.00 Price Target at Jefferies Group LLCAratana Therapeutics, Inc. (PETX) Given a $9.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - November 18 at 12:52 PM
Aratana Therapeutics, Inc. (PETX) Coverage Initiated by Analysts at HC WainwrightAratana Therapeutics, Inc. (PETX) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - November 18 at 11:38 AM
Aratana Therapeutics, Inc. (PETX) Downgraded by Zacks Investment Research to "Hold"Aratana Therapeutics, Inc. (PETX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - November 18 at 6:04 AM
Aratana Therapeutics, Inc. (PETX) to Post FY2017 Earnings of ($1.04) Per Share, Jefferies Group ForecastsAratana Therapeutics, Inc. (PETX) to Post FY2017 Earnings of ($1.04) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 17 at 8:30 PM

SEC Filings

Aratana Therapeutics (NASDAQ:PETX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aratana Therapeutics (NASDAQ:PETX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aratana Therapeutics (NASDAQ PETX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.